Compass Therapeutics Inc. (CMPX)
$1.43
Performance
- $1.43$1.50$1.43
0.0%
Downside
Day's Volatility :4.67%
Upside
4.67%
- $0.77$2.34$1.43
46.5%
Downside
52 Weeks Volatility :67.31%
Upside
38.89%
Returns
| Period | Compass Therapeutics Inc. | Index (Russel 2000) |
|---|---|---|
3 Months | 9.16% | 0.0% |
6 Months | -25.52% | 0.0% |
1 Year | -37.83% | 0.0% |
3 Years | -64.07% | -22.3% |
Highlights
Market Capitalization | 196.8M |
Book Value | $1.06 |
Earnings Per Share (EPS) | -0.35 |
Wall Street Target Price | 8.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -1770.0% |
Return On Assets TTM | -20.58% |
Return On Equity TTM | -30.05% |
Revenue TTM | 850.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -54.5M |
Diluted Eps TTM | -0.35 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.42 |
EPS Estimate Next Year | -0.51 |
EPS Estimate Current Quarter | -0.09 |
EPS Estimate Next Quarter | -0.1 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 459.44%
Technicals Summary
Sell
Neutral
Buy
Compass Therapeutics Inc. is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Compass Therapeutics Inc. | 58.89% | -25.52% | -37.83% | -64.07% | -64.07% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Compass Therapeutics Inc. | NA | NA | NA | -0.42 | -0.3 | -0.21 | NA | 1.06 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Compass Therapeutics Inc. | Buy | $196.8M | -64.07% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Compass Therapeutics Inc.
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 74.9%
Institutional Holdings
Orbimed Advisors, LLC
16.25%Adage Capital Partners Gp LLC
8.09%Blackstone Inc
5.59%BlackRock Inc
4.81%Rock Springs Capital Management LP
4.01%HHG PLC
3.79%
Company Information
compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond
Organization | Compass Therapeutics Inc. |
Employees | 32 |
CEO | Dr. Thomas J. Schuetz M.D., Ph.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$1.43
-4.03%
Keyarch Acquisition Corp
$1.43
-4.03%
Connexa Sports Technologies Inc
$1.43
-4.03%
Us Value Etf
$1.43
-4.03%
First Wave Biopharma Inc
$1.43
-4.03%
Global X Msci Next Emerging
$1.43
-4.03%
Fat Projects Acquisition Corp
$1.43
-4.03%
Capital Link Global Fintech
$1.43
-4.03%
Applied Uv Inc
$1.43
-4.03%